Reproducibility is an integral part of research, and in particular in life science research where multiple variables are inherent to experiments with biological reagents. Particularly, antibodies are a central and critical part of life science research but reproducibility is a challenge often associated with their success across a variety of applications. In these webinars, we will equip attendees with various approaches to safeguard their research through recombinant antibodies, cell culturing procedures, antibody protein sequences and reference identifiers.
10 – 10:25am ET: Andrew Bradbury, CSO at Specifica, spearheaded the antibody reproducibility movement by penning a seminal Nature paper in 2015 on the reproducibility crisis. Dr. Bradbury will begin today’s series by providing an overview of research reproducilibity in the life sciences industry, as well as describe how antibody libraries might help address the problem.
10:25 – 10:55am ET: Michael Fiebig, VP Product Portfolio & Innovation at Absolute Antibody, will be outlining the benefits of recombinant antibodies, which are absolutely defined by their amino acid sequences and manufactured in vitro using synthetic genes. Compared to traditional hybridoma-produced monoclonal antibodies, recombinant antibodies offer significant benefits including ensuring bath-to-batch reproducibility.
10:55 – 11:20am ET: Alicia Henn, CSO at BioSpherix, notes that nobody writes in their SOP, “Carry out the following cell culture steps in uncontrolled physiologically irrelevant room air.” Yet, that is exactly what happens in traditional cell culture operations. In this webinar, Dr. Henn will review the Cytocentric features of systems to keep cells and tissues in reproducibile conditions.
11:20 – 11:50am ET: Zac McDonald, Senior Scientist and Manager of Proteomics Research, and Anthony Stajduhar, Director of International BD at Rapid Novor will be reviewing the REmAb® protein sequencing platform including proteomic approaches, bioinformatic analysis and future capabilities. Protein sequencing immortalizes research reagents with 100% coverage and 100% accuracy, requiring access to only the protein itself.
11:50am – 12:15pm ET: Anita Bandrowski, CEO of SciCrunch and head of the Resource Identification Initiative, will be discussing why it’s necessary to incorporate more Rigor and Transparency into scientific publications for ensuring future reproducibility. Dr. Bandrowski will discuss efforts that include centralizing a research portal to promote research resource identification, discovery and reuse by assigning research resource identifiers (RRIDs).
Attendees will learn various approaches to safeguard their research and overcome reproducibility challenges in the Life Sciences industry.
Andrew Bradbury, PhD
Founder and CSO
Dr. Bradbury is the Chief Scientific Officer and Co-founder of Specifica, a biotechnology company that creates exclusive, high performance antibody libraries for the drug discovery efforts of pharma and biotech companies. He has 30 years of experience in the field of recombinant antibodies and display technologies, and throughout his career, he has developed and employed novel technologies in the antibody engineering and discovery fields. Prior to co-founding Specifica, he was a group leader and research scientist for nearly 18 years at Los Alamos National Laboratory. He has published over 140 peer-reviewed papers and is the lead inventor on numerous patents and patent applications.
Michael Fiebig, PhD
VP Product Portfolio & Innovation
Dr. Fiebig studied Biochemistry before obtaining his doctoral degree at the Sir William Dunn School of Pathology, University of Oxford. With a background in both wet-lab and bioinformatic methods, Michael is developing an extensive catalog of recombinant antibodies that enables Absolute Antibody customers and business partners to harness the benefits of recombinant antibody technology.
Alicia D. Henn, PhD, MBA
Chief Scientific Officer
Previously, Dr. Henn was a researcher in the Center for Biodefense Immune Modeling at the University of Rochester and at Vaccinex, LLC. At BioSpherix, Dr. Henn has crafted the company’s first scientific program, collaborating with scientists worldwide to advance cell-based therapies and research. Dr. Henn also established a comprehensive training program for customers adopting Cytocentric Systems. Dr. Henn founded and manages the In Vitro Reproducibility group on LinkedIn. She also writes the Cytocentric Blog, promoting clonable, aseptic and physiologically relevant cell production environments for better scientific reproducibility and translatability.
Zac McDonald, PhD
Senior Scientist and Manager of Proteomics Research
Rapid Novor, Inc.
Dr. McDonald completed his PhD in Biochemistry in the Molecular and Cell Biology Department at the University of Cape Town. During his PhD work, he was introduced to the power and potential of mass spectrometry (MS)-based proteomics while conducting research at the Max Planck Institute in Golm, Germany. For the last decade, Zac has worked on a range of proteomics projects both as a scientist and research manager in core facilities, and most recently at Rapid Novor, Inc., in Kitchener, Ontario, Canada. Zac is currently focused on the application of MS to disease monitoring in Multiple Myeloma and on establishing a clinical proteomics platform at Rapid Novor.
Anita Bandrowski, PhD
Founder and CEO
Dr. Bandrowski is a neurophysiologist by training that has dedicated the past decade to neuro-informatics to increase access to and utilization of neuroscience data. She is the Founder and CEO of SciCrunch, a technology startup focused on making sense of Big biological data. Anita is also the scientific lead of the Neuroscience Information Framework (NIF) project, which has grown into the largest source of neuroscience data and tools on the web under her direction. Thanks to her neuroscience background and her experience at NIF, Anita has a unique global perspective on issues in data sharing and utilization in the neurosciences and has gained considerable insight and expertise in working with diverse biomedical data. Anita also serves as the lead for the Resource Identification Initiative, a FORCE11, the Future of Research Communications and e-Scholarship, group dedicated to transforming scholarly communication.
Cost: No Cost!